Eliminating adverse drug events at Ascension Health.

Eliminating adverse drug events at Ascension Health. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Eliminating adverse drug events at Ascension Health. Abstract Text:

Kerry Butler,Paul Mollo,Jane L Gale,Deborah A Rapp,Kerry Butler,Paul Mollo,Jane L Gale,Deborah A Rapp,

Improvement in ADE rate did not occur at either hospital with any one particular intervention, or even after several conventional interventions had time to take effect. Instead, instituting many simultaneous system changes, proactively assessing risk, and expanding the scope of intervention were each essential to sustaining the described reductions in harm. The next step toward eliminating ADEs requires simultaneous communication across systems in a way that is manageable, approachable, and adaptable, and that supports the elements of change. A system of mutually informed processes--from medication selection and entry through preparation and dispensing, administration, monitoring, and reconciliation--should result in safe, patient-centered, reliable, and efficient medication use. In March 2007, Ascension Health, drawing on the work described in this article, began developing such a system.

Eliminating adverse drug events at Ascension Health. Publishing Authors By Initials

K Butler,P Mollo,JL Gale,DA Rapp,K Butler,P Mollo,JL Gale,DA Rapp,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Eliminating adverse drug events at Ascension Health. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Joint Commission journal on quality and patient sa

VOLUME: 33

Page Numbers: 527-36

Journal Abbreviation:

ISSN: 1553-7250

DAY: 5

MONTH: Sep

YEAR: 2007

Eliminating adverse drug events at Ascension Health. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101238023

Eliminating adverse drug events at Ascension Health. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Eliminating adverse drug events at Ascension Health. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Eliminating adverse drug events at Ascension Health.

AFFILIATION: Saint Thomas Hospital, Nashville, Tennessee, USA. kbutler@stthomas.org

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Jt Comm J Qual Patient Saf

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Eliminating adverse drug events at Ascension Health Related Publications

• (Na+,K+)-activated adenosinetriphosphatase and hypertension in DAHL salt- sensitive and -resistant rats.
• A controlled comparison between imipramine and protriptyline.
• A phylogenetic theory of wit and humor.
• Apoptosis regulation by Raf, Bcl-2, and R-Ras.
• Basic principles of roentgenology.
• Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation.
• Chlorophyll, the green wonder drug.
• Detection of clinically silent infarcts after carotid endarterectomy by use of diffusion-weighted imaging.
• Dysmenorrhea.
• Eliminating adverse drug events at Ascension Health.
• Evaluation of conceptual selling(r) as a job development planning process.
• Lack of effects of maternal salt intake on blood pressure of offspring in Dahl salt-sensitive rats.
• Lexical and post-lexical phonological representations in spoken production.
• MRI of geometric and compositional features of vulnerable carotid plaque.
• Normal values for serum amylase and maltase in dogs and the effect of maltase on the saccharogenic method of determining amylase in serum.
• Objective evaluation of EEG amplitude in chronic schizophrenic patients during a controlled trial of pimozide and trifluoperazine.
• Organic rodenticides.
• Quantitation of renal renin and renin mRNA in Dahl rats in response to provocative stimuli.
• Reactive plasticity in the dentate gyrus following bilateral entorhinal cortex lesions in cynomolgus monkeys.
• Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism.
• Responses to calcium of chemically skinned vascular smooth muscle from spontaneously hypertensive rats.
• Serum levels of phenylalanine and tyrosine in Huntington's chorea.
• Simulation of the MRI measurement of diffusion in realistic neural tissue models.
• The Ras-Raf relationship: an unfinished puzzle.
• The role of Raf kinases in development and growth of tumors.
• The strengths perspective: proving "my strengths" and '"it work".
• [Herpesvirus and human cancer]
• [Not Available.]
• [Postpartum cerebral thrombophlebitis; cure.]
• [The leukocyte migration test (LMT) in carcinoma of the stomach and nonmalignant stomach diseases : evidence for the appearance of tumor-associated antigens]